A citation-based method for searching scientific literature

Azadeh Hajmirza, Anouk Emadali, Arnaud Gauthier, Olivier Casasnovas, Rémy Gressin, Mary B Callanan. Biomedicines 2018
Times Cited: 81







List of co-cited articles
578 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Selective inhibition of BET bromodomains.
Panagis Filippakopoulos, Jun Qi, Sarah Picaud, Yao Shen, William B Smith, Oleg Fedorov, Elizabeth M Morse, Tracey Keates, Tyler T Hickman, Ildiko Felletar,[...]. Nature 2010
29


Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA.
Bo Huang, Xiao-Dong Yang, Ming-Ming Zhou, Keiko Ozato, Lin-Feng Chen. Mol Cell Biol 2009
402
19

BRD4 and Cancer: going beyond transcriptional regulation.
Benedetta Donati, Eugenia Lorenzini, Alessia Ciarrocchi. Mol Cancer 2018
216
18

Suppression of inflammation by a synthetic histone mimic.
Edwige Nicodeme, Kate L Jeffrey, Uwe Schaefer, Soren Beinke, Scott Dewell, Chun-Wa Chung, Rohit Chandwani, Ivan Marazzi, Paul Wilson, Hervé Coste,[...]. Nature 2010
17

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Johannes Zuber, Junwei Shi, Eric Wang, Amy R Rappaport, Harald Herrmann, Edward A Sison, Daniel Magoon, Jun Qi, Katharina Blatt, Mark Wunderlich,[...]. Nature 2011
16

NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis.
Jonathan D Brown, Charles Y Lin, Qiong Duan, Gabriel Griffin, Alexander Federation, Ronald M Paranal, Steven Bair, Gail Newton, Andrew Lichtman, Andrew Kung,[...]. Mol Cell 2014
381
16

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Lei-lei Fu, Mao Tian, Xiang Li, Jing-jing Li, Jian Huang, Liang Ouyang, Yonghui Zhang, Bo Liu. Oncotarget 2015
160
14

Two faces of brd4: mitotic bookmark and transcriptional lynchpin.
Ballachanda N Devaiah, Dinah S Singer. Transcription 2013
61
19

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.
Omer Gilan, Inmaculada Rioja, Kathy Knezevic, Matthew J Bell, Miriam M Yeung, Nicola R Harker, Enid Y N Lam, Chun-Wa Chung, Paul Bamborough, Massimo Petretich,[...]. Science 2020
151
14

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Jake E Delmore, Ghayas C Issa, Madeleine E Lemieux, Peter B Rahl, Junwei Shi, Hannah M Jacobs, Efstathios Kastritis, Timothy Gilpatrick, Ronald M Paranal, Jun Qi,[...]. Cell 2011
13


Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA.
Z Zou, B Huang, X Wu, H Zhang, J Qi, J Bradner, S Nair, L-F Chen. Oncogene 2014
170
12

Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy.
Ali Alqahtani, Khalil Choucair, Mushtaq Ashraf, Danae M Hammouda, Abduraham Alloghbi, Talal Khan, Neil Senzer, John Nemunaitis. Future Sci OA 2019
149
12

Histone recognition and large-scale structural analysis of the human bromodomain family.
Panagis Filippakopoulos, Sarah Picaud, Maria Mangos, Tracy Keates, Jean-Philippe Lambert, Dalia Barsyte-Lovejoy, Ildiko Felletar, Rudolf Volkmer, Susanne Müller, Tony Pawson,[...]. Cell 2012
962
12

Bromodomains: a new target class for drug development.
Andrea G Cochran, Andrew R Conery, Robert J Sims. Nat Rev Drug Discov 2019
185
12

The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription.
Moon Kyoo Jang, Kazuki Mochizuki, Meisheng Zhou, Ho-Sang Jeong, John N Brady, Keiko Ozato. Mol Cell 2005
865
11

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
Mark A Dawson, Rab K Prinjha, Antje Dittmann, George Giotopoulos, Marcus Bantscheff, Wai-In Chan, Samuel C Robson, Chun-wa Chung, Carsten Hopf, Mikhail M Savitski,[...]. Nature 2011
11

Targeting bromodomains: epigenetic readers of lysine acetylation.
Panagis Filippakopoulos, Stefan Knapp. Nat Rev Drug Discov 2014
828
11

Selective inhibition of tumor oncogenes by disruption of super-enhancers.
Jakob Lovén, Heather A Hoke, Charles Y Lin, Ashley Lau, David A Orlando, Christopher R Vakoc, James E Bradner, Tong Ihn Lee, Richard A Young. Cell 2013
11

BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice.
Erica Korb, Margo Herre, Ilana Zucker-Scharff, Robert B Darnell, C David Allis. Nat Neurosci 2015
145
11

Emerging roles of and therapeutic strategies targeting BRD4 in cancer.
Mary E White, Joelle M Fenger, William E Carson. Cell Immunol 2019
57
15

Brd4 and HEXIM1: multiple roles in P-TEFb regulation and cancer.
Ruichuan Chen, Jasper H N Yik, Qiao Jing Lew, Sheng-Hao Chao. Biomed Res Int 2014
55
14

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
Sandy Amorim, Anastasios Stathis, Mary Gleeson, Sunil Iyengar, Valeria Magarotto, Xavier Leleu, Franck Morschhauser, Lionel Karlin, Florence Broussais, Keyvan Rezai,[...]. Lancet Haematol 2016
269
9

Super-enhancers in the control of cell identity and disease.
Denes Hnisz, Brian J Abraham, Tong Ihn Lee, Ashley Lau, Violaine Saint-André, Alla A Sigova, Heather A Hoke, Richard A Young. Cell 2013
9

Brd4 is on the move during inflammation.
Yali Xu, Christopher R Vakoc. Trends Cell Biol 2014
24
33

Small-molecule inhibition of BRDT for male contraception.
Martin M Matzuk, Michael R McKeown, Panagis Filippakopoulos, Qinglei Li, Lang Ma, Julio E Agno, Madeleine E Lemieux, Sarah Picaud, Richard N Yu, Jun Qi,[...]. Cell 2012
257
9

Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma.
Tie Xiang, Jin-Yu Bai, Chang She, Dao-Jiang Yu, Xiao-Zhong Zhou, Tian-Lan Zhao. Cell Signal 2018
28
25

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
Marie-Magdelaine Coudé, Thorsten Braun, Jeannig Berrou, Mélanie Dupont, Sibyl Bertrand, Aline Masse, Emmanuel Raffoux, Raphaël Itzykson, Marc Delord, Maria E Riveiro,[...]. Oncotarget 2015
176
8


Functions of bromodomain-containing proteins and their roles in homeostasis and cancer.
Takao Fujisawa, Panagis Filippakopoulos. Nat Rev Mol Cell Biol 2017
278
8

Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4.
Francesca Zanconato, Giusy Battilana, Mattia Forcato, Letizia Filippi, Luca Azzolin, Andrea Manfrin, Erika Quaranta, Daniele Di Biagio, Gianluca Sigismondo, Vincenza Guzzardo,[...]. Nat Med 2018
151
8

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.
Céline Berthon, Emmanuel Raffoux, Xavier Thomas, Norbert Vey, Carlos Gomez-Roca, Karen Yee, David Christopher Taussig, Keyvan Rezai, Christophe Roumier, Patrice Herait,[...]. Lancet Haematol 2016
276
8

BRD4 directs hematopoietic stem cell development and modulates macrophage inflammatory responses.
Anup Dey, Wenjing Yang, Anne Gegonne, Akira Nishiyama, Richard Pan, Ryoji Yagi, Alex Grinberg, Fred D Finkelman, Karl Pfeifer, Jinfang Zhu,[...]. EMBO J 2019
58
12

Master transcription factors and mediator establish super-enhancers at key cell identity genes.
Warren A Whyte, David A Orlando, Denes Hnisz, Brian J Abraham, Charles Y Lin, Michael H Kagey, Peter B Rahl, Tong Ihn Lee, Richard A Young. Cell 2013
8

Targeting Brd4 for cancer therapy: inhibitors and degraders.
Yingchao Duan, Yuanyuan Guan, Wenping Qin, Xiaoyu Zhai, Bin Yu, Hongmin Liu. Medchemcomm 2018
63
11

Involvement of Brd4 in different steps of the papillomavirus life cycle.
Thomas Iftner, Juliane Haedicke-Jarboui, Shwu-Yuan Wu, Cheng-Ming Chiang. Virus Res 2017
33
18

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Garrett W Rhyasen, Maureen M Hattersley, Yi Yao, Austin Dulak, Wenxian Wang, Philip Petteruti, Ian L Dale, Scott Boiko, Tony Cheung, Jingwen Zhang,[...]. Mol Cancer Ther 2016
94
7

Structure and ligand of a histone acetyltransferase bromodomain.
C Dhalluin, J E Carlson, L Zeng, C He, A K Aggarwal, M M Zhou. Nature 1999
7

Selective degradation of BET proteins with dBET1, a proteolysis-targeting chimera, potently reduces pro-inflammatory responses in lipopolysaccharide-activated microglia.
Kelly M DeMars, Changjun Yang, Carolina I Castro-Rivera, Eduardo Candelario-Jalil. Biochem Biophys Res Commun 2018
35
17


Clinical trials for BET inhibitors run ahead of the science.
Guillaume Andrieu, Anna C Belkina, Gerald V Denis. Drug Discov Today Technol 2016
153
7

RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.
Ravi Jahagirdar, Sarah Attwell, Suzana Marusic, Alison Bendele, Narmada Shenoy, Kevin G McLure, Dean Gilham, Karen Norek, Henrik C Hansen, Raymond Yu,[...]. Mol Pharmacol 2017
34
17

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
Sarah Picaud, Christopher Wells, Ildiko Felletar, Deborah Brotherton, Sarah Martin, Pavel Savitsky, Beatriz Diez-Dacal, Martin Philpott, Chas Bountra, Hannah Lingard,[...]. Proc Natl Acad Sci U S A 2013
284
7

Bromodomain inhibitors and cancer therapy: From structures to applications.
Montserrat Pérez-Salvia, Manel Esteller. Epigenetics 2017
156
7

Bromodomain: an acetyl-lysine binding domain.
Lei Zeng, Ming Ming Zhou. FEBS Lett 2002
521
7

The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.
Romain Gosmini, Van Loc Nguyen, Jérôme Toum, Christophe Simon, Jean-Marie G Brusq, Gael Krysa, Olivier Mirguet, Alizon M Riou-Eymard, Eric V Boursier, Lionel Trottet,[...]. J Med Chem 2014
108
7

Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases.
Ewelina Kulikowski, Brooke D Rakai, Norman C W Wong. Med Res Rev 2021
34
17

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.
Sarina A Piha-Paul, Jasgit C Sachdev, Minal Barve, Patricia LoRusso, Russell Szmulewitz, Sapna Pradyuman Patel, Primo N Lara, Xiaotian Chen, Beibei Hu, Kevin J Freise,[...]. Clin Cancer Res 2019
70
8

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Emily J Faivre, Keith F McDaniel, Daniel H Albert, Srinivasa R Mantena, Joshua P Plotnik, Denise Wilcox, Lu Zhang, Mai H Bui, George S Sheppard, Le Wang,[...]. Nature 2020
146
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.